Our T2 Magnetic Resonance (T2MR) technology platform can detect pathogens, biomarkers and other abnormalities in a broad range of unpurified sample types, including whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, T2MR has the potential for numerous additional applications beyond our current pipeline.
T2 Biosystems is selectively establishing alliances with dynamic organizations that have the capability and desire to develop additional breakthrough applications utilizing our T2MR platform. Partnership opportunities for co-development and commercialization include our current products as well as potential new applications for T2MR, ranging from companion diagnostics to research as well as non-healthcare applications.
We continue to pursue a strategic partnership for the commercial development of the T2Lyme™ Panel as an LDT.
Interested in discussing additional breakthrough applications utilizing our T2MR technology?
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Read this case study to learn how T2Candida enabled the detection of candidemia 29 hours before a positive blood culture was returned, allowing for the rapid initiation of targeted antifungal therapy in a critically ill COVID-19 patient.
The SC Pharmacy Association's Annual Convention is takes place June 25th in Charleston, SC. Visit our booth to learn more about how we can support your institution’s #stewardship initiatives with the T2Bacteria and T2Candida Panels. #Pharmacy#AMR